US 12180296
Cross species single domain antibodies targeting mesothelin for treating solid tumors
granted A61KA61K2039/505A61K2239/31
Quick answer
US patent 12180296 (Cross species single domain antibodies targeting mesothelin for treating solid tumors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 40
- CPC classes
- A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/55